Dogwood Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Dogwood Therapeutics has a total shareholder equity of $949.4K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.3M and $1.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.04m |
| Equity | US$949.43k |
| Total liabilities | US$1.33m |
| Total assets | US$2.28m |
Recent financial health updates
Recent updates
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Aug 24
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?
May 11Virios Therapeutics slides 11% postmarket on proposed stock offering
Sep 19Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Aug 11Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jun 25Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Mar 09Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Nov 02Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jul 19Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study
Jun 04Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans
Mar 31Virios Therapeutics gains 10% on research deal in irritable bowel syndrome
Feb 01Virios Therapeutics prices IPO at $10
Dec 17Financial Position Analysis
Short Term Liabilities: DWTX's short term assets ($2.3M) exceed its short term liabilities ($1.3M).
Long Term Liabilities: DWTX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DWTX is debt free.
Reducing Debt: DWTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DWTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DWTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.2% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 00:32 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dogwood Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |
| David Bautz | Zacks Small-Cap Research |